Phase III results show Roche's subcutaneous formulation of Tecentriq is comparable to intravenous Tecentriq and delivered in minutes
Administered under the skin, the subcutaneous formulation reduces time spent receiving treatment to approx. seven minutes, compared with 30-60 minutes for IV infusion1Roche has submitted data from the IMscin001 study to health authorities, seeking approval for the subcutaneous option across all approved indications of IVTecentriq If approved,Tecentriq would be Roche ’s fourth subcutaneous cancer therapy,2-4 helping to improve the treatment experience for patients. In addition, it could save resources for healthcare systems5-10Basel, 1 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new pivotal data ...
Source: Roche Investor Update - December 1, 2022 Category: Pharmaceuticals Source Type: news
Rituximab Raises Remission Rate in GPA Vasculitis Rituximab Raises Remission Rate in GPA Vasculitis
Remission at 6 months was recorded in 73.1% of rituximab-treated patients and 40.1% of cyclophosphamide-treated patients in a multicenter target trial emulation.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 30, 2022 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Safer Alternative to Cyclophosphamide at Hand for ILD?
(MedPage Today) -- PHILADELPHIA -- Rituximab (Rituxan) matched IV cyclophosphamide for improving lung function in patients with interstitial lung disease (ILD) related to systemic sclerosis and other connective tissue diseases, and was associated... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - November 14, 2022 Category: Rheumatology Source Type: news
CTD-ILD: Rituximab'a Reasonable Alternative to Cyclophosphamide'CTD-ILD: Rituximab'a Reasonable Alternative to Cyclophosphamide '
A clinical trial found that rituximab and cyclophosphamide had similar outcomes for interstitial lung disease associated with connective tissue disorders.MDedge News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - November 14, 2022 Category: Internal Medicine Tags: Rheumatology News Source Type: news
Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs
Interim data from phase III HAVEN 7 study reinforceHemlibra ’s efficacy and safety in infants with severehaemophilia A without factor VIII inhibitors1New and updated data support use ofPolivy in diffuse large B-cell lymphoma, including its potential as a treatment option for previously untreated patients2New and updated data for innovative CD20xCD3 T-cell engaging bispecific antibodiesLunsumio andglofitamab further enhance their potential as effective, off-the-shelf, fixed-duration treatment options for people with lymphoma3,4,5,6,7First phase III data forcrovalimab show the co-primary efficacy endpoints were met, with s...
Source: Roche Media News - November 3, 2022 Category: Pharmaceuticals Source Type: news
Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs
Interim data from phase III HAVEN 7 study reinforceHemlibra ’s efficacy and safety in infants with severehaemophilia A without factor VIII inhibitors1New and updated data support use ofPolivy in diffuse large B-cell lymphoma, including its potential as a treatment option for previously untreated patients2New and updated data for innovative CD20xCD3 T-cell engaging bispecific antibodiesLunsumio andglofitamab further enhance their potential as effective, off-the-shelf, fixed-duration treatment options for people with lymphoma3,4,5,6,7First phase III data forcrovalimab show the co-primary efficacy endpoints were met, with s...
Source: Roche Investor Update - November 3, 2022 Category: Pharmaceuticals Source Type: news
Higher Relapse Rate With Rituximab vs Ocrelizumab in MS Registry Data
(MedPage Today) -- Rituximab (Rituxan) did not show noninferiority compared with ocrelizumab (Ocrevus) in relapsing-remitting multiple sclerosis (MS), according to registry data.
The annualized relapse rate (ARR) was higher in MS patients treated... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - November 2, 2022 Category: Neurology Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Group salesup 2%[1] at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye diseases)US approval...
Source: Roche Investor Update - October 18, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Basel, 18 October 2022Group salesup 2%1 at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye ...
Source: Roche Media News - October 18, 2022 Category: Pharmaceuticals Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Rituximab Studied as Add-On Therapy for New-Onset Myasthenia Gravis
TUESDAY, Oct. 4, 2022 -- A single infusion of rituximab early after the onset of generalized myasthenia gravis improves outcomes at 16 weeks, according to a study published online Sept. 19 in JAMA Neurology.
Fredrik Piehl, M.D., Ph.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 4, 2022 Category: Pharmaceuticals Source Type: news
Ibrutinib With Rituximab in Mantle Cell Lymphoma Ibrutinib With Rituximab in Mantle Cell Lymphoma
Combination therapy with ibrutinib and rituximab appears to be effective among elderly patients with mantle cell lymphoma, but cardiac toxicity remains a concern.Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2022 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Recent Neurology Data Highlight Treatments to Avoid Recent Neurology Data Highlight Treatments to Avoid
Although recent neurology literature brought good news for rituximab in relapsing-remitting multiple sclerosis, the results were decidedly more mixed for other treatments, says Dr Christoph Diener.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 25, 2022 Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news
U.S. FDA Approves IMBRUVICA ® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
August 24, 2022 (HORSHAM, PA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy. This milestone marks the first pediatric indication for IMBRUVICA® and the introduction of a new oral suspension formulation for patients ages one to less than 12. IMBRUVICA® is now the first FDA-approved therapy for these younger patients who previously had no approv...
Source: Johnson and Johnson - August 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA accepts supplemental Biologics License Application for Roche ’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
First new treatment regimen in more than 20 years to significantly improve outcomes in people with this fast-growing type of lymphomaApplication is based on pivotal data from the phase III POLARIX study showing Polivy plus R-CHP significantly reduced therisk of disease progression, relapse or death with comparable safety versus the standard of care, R-CHOPVarious combination studies with Polivy and the company ' s CD20xCD3 bispecifics in diffuse large B-cell lymphoma are ongoingBasel, 16 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the compan...
Source: Roche Investor Update - August 16, 2022 Category: Pharmaceuticals Source Type: news
